All relevant data are within the paper and its Supporting Information files.

Introduction {#sec006}
============

Methicillin-resistant *Staphylococcus aureus* (MRSA) is a common pathogen which causes infections, especially among patients who undergo dialysis.\[[@pone.0193585.ref001]\] Vancomycin is an antibiotic glycopeptide which kills bacteria by inhibiting cell wall synthesis, and it is the first line treatment for MRSA infection if minimum inhibitory concentration (MIC) is lower than 1 mg/L \[[@pone.0193585.ref002]\]. The clinical efficacy of vancomycin is best predicted by the area under the curve over 24 hours (AUC~24~) to the MIC ratio, and a target AUC~24~/MIC ratio of ≥ 400 is recommended by the Infectious Diseases Society of America (IDSA) Practice Guideline\[[@pone.0193585.ref002]--[@pone.0193585.ref004]\]. The trough serum concentration (C~trough~) of vancomycin is recommended as a surrogate for the AUC~24~ and should be maintained between 15--20 mg/L to achieve an AUC~24~/MIC ≥ 400 when MIC is ≤ 1 mg/L\[[@pone.0193585.ref002], [@pone.0193585.ref005]\]. However, among previous studies that investigated the association between vancomycin AUC~24~/MIC or C~trough~ and treatment outcome, few examined renal failure patients who received renal replacement therapy such as hemodialysis (HD)\[[@pone.0193585.ref003], [@pone.0193585.ref004], [@pone.0193585.ref006], [@pone.0193585.ref007]\]. The immune function was changed in renal failure patients, which may affect treatment outcome than that in general population.\[[@pone.0193585.ref008]\] Therefore, the AUC~24~/MIC or C~trough~ target may be different in this vulnerable population. As a result, current vancomycin dosing regimen for HD patients relies mainly on extrapolation or modeling.\[[@pone.0193585.ref009]\] Although pre- or post-HD serum concentration monitoring has been adopted as a common clinical practice for years in vancomycin-treated patients with renal failure under HD, the best time of sampling remains controversial\[[@pone.0193585.ref010]\]. Moreover, previous studies all focused on developing specific dosing protocols in renal failure patients to achieve the target vancomycin serum concentration of 10--20 mg/L\[[@pone.0193585.ref011]--[@pone.0193585.ref015]\]. Nonetheless, evidence is still lacking to show any correlation between pre-dialysis vancomycin trough serum concentration (C~pre-HD~) and the clinical outcomes in this patient population. Our aim is to investigate the relationship between C~pre-HD~ and treatment outcomes of MRSA bacteremia in patients undergoing HD.

Materials and methods {#sec007}
=====================

This retrospective study was conducted in the National Taiwan University Hospital (NTUH), which is a tertiary medical center with a 2600-bed capacity in northern Taiwan., and patients profiles during January 2013 to June 2016 of the Integrated Medical Database (NTUH-iMD) was used for patient enrollment. This study had been approved by the Research Ethics Committee of NTUH (201602044RINB). Adult patients (≥ 20 yrs) with chronic renal failure undergoing HD three times per week were included if they had documented MRSA bacteremia, and received vancomycin treatment within 72 hours after the blood sample from which the MRSA was first isolated. MRSA bacteremia was defined as at least one set of blood culture that was collected when systemic inflammatory response syndrome was present and yielded MRSA. Patients were excluded for missing C~pre-HD~ measurements during the treatment course, vancomycin use less than a week, absence of following blood cultures collected after vancomycin treatment, ever receiving other antibiotics for MRSA treatment (such as daptomycin, linezolid, teicoplanin and tigecycline) within 7 days before vancomycin treatment, receiving continuous renal replacement therapy (CRRT) during vancomycin treatment or daily urine output over than 400 mL.

The dosing regimen of vancomycin for patients under HD in our institution was 15--20 mg/kg as a loading dose (LD), followed by 7--10 mg/kg after each HD as maintenance doses (MD). The sampling time of C~pre-HD~ was within one hour before the third HD session since giving one LD and two MD. The vancomycin serum concentrations were measured by a chemiluminescent microparticle immunoassay (ARCHITECT i2000SR immunoassay analyzer, Abbott Laboratories, Abbott Park, Illinois, USA). The limit of detection (sensitivity) was 0.24 mg/L, and the coefficients of variation at 7.0, 35.0, and 75.0 mg/L were \< 5%. For hemodialysis, the blood and dialysate flow rates were set at 200 and 500 mL/min, respectively. The dialysis lasted 4 hour each time and the dialyzers used were F6HPS, FX60, FX80, or FX100 by nephrologist's decision (Fresenius Medical Care, Bad Homburg, Germany).

A standardized case report form was used to collected data including demographic characteristics (sex, age, height, and weight), the Charlson Comorbidity Index (CCI) and underlying diseases, sources and sites of infection (based on medical records and culture sampling sites), subsequent blood cultures results, immunosuppressant usage (i.e. prednisolone ≥ 10mg/day or other corticosteroids of equivalent potency, calcineurin inhibitors, mechanistic target of rapamycin (mTOR) inhibitors, azathioprine, and mycophenolate mofetil), catheterization, catheter removal, vancomycin doses and duration of treatment, C~pre-HD~, MIC of vancomycin for MRSA, concurrent antibiotics usage, shock status (use of vasopressors or inotropics), and 30-day mortality. The MIC of vancomycin for the first isolate was determined by the broth microdilution method according to the Guidelines of the Clinical and Laboratory Standards Institute (CLSI) except for two MIC of vancomycin that was determined by E-test according to the manufacturer's instruction.\[[@pone.0193585.ref016]\] Because AUC~24~ and C~pre-HD~ are highly correlated in patients receiving HD, we calculate C~pre-HD~/MIC as a surrogate of AUC~24~/MIC to evaluate its effect on treating MRSA bacteremia.\[[@pone.0193585.ref009]\]

Treatment failure was defined as persistent bacteremia after ≥ 7 days of vancomycin treatment, or recurrent MRSA infection within 30 days after the first negative conversion of blood culture.\[[@pone.0193585.ref002]\]

Data were described as mean ± standard deviation or number with percentage. The two-tailed independent *t* test was used for continuous data, and either Chi-square or Fisher's exact test was used for categorical data. A *p*-value of 0.05 or lower was considered statistically significant. The receiver operating characteristic (ROC) curve was used to determine the optimal cut-off point of C~pre-HD~/MIC, which had the maximum Youden index. The statistical analysis was performed by SPSS 18 (SPSS Inc, Chicago, Illinois, USA).

Results {#sec008}
=======

Sixty-five HD patients who received vancomycin due to MRSA bacteremia were initially enrolled. Twenty-three patients were excluded for lacking following blood culture collected (n = 8), missing pre-dialysis serum level data (n = 3), using other antibiotics within 7 days before vancomycin treatment (n = 7), or receiving CRRT (n = 5) during vancomycin treatment. Forty-two patients were available for the final analysis.

Fifteen patients (36%) were successfully treated, and the other 27 were classified as treatment failure (64%). In the treatment failure group, 25 patients had persistent bacteremia, and 2 had recurrent MRSA infection, which two weeks course of antibiotics was completed before. Although there were no significant differences in baseline demographics, underlying disease, sources of bacteremia, or vancomycin regimens between the success and failure group, more patients received immunosuppressants in treatment failure group ([Table 1](#pone.0193585.t001){ref-type="table"}). Catheters were all removed in both groups after confirming it as infection source. C~pre-HD~ values were not significantly different between the success and failure groups (17.40 ± 4.55 vs. 15.22 ± 4.24 mg/L, *p* = 0.139) ([Table 2](#pone.0193585.t002){ref-type="table"}). However, C~pre-HD~/MIC was significantly higher in the success group compared to that of the failure group (22.80 ± 10.90 vs. 14.94 ± 6.11, *p* = 0.019). There was also no significant difference in 30-day mortalities between the success and failure groups (11% vs 19%, *p* = 0.666).

10.1371/journal.pone.0193585.t001

###### Clinical characteristics and vancomycin dose, classified by vancomycin treatment outcomes.

![](pone.0193585.t001){#pone.0193585.t001g}

                                               Total patients (N = 42)   Success group (N = 15)   Failure group (N = 27)   *p* value
  -------------------------------------------- ------------------------- ------------------------ ------------------------ -----------
  Age                                          69.00 ± 14.81             71.80 ± 13.23            67.44 ± 15.63            0.346
  Height (cm) (mean ± standard deviation)      159.57 ± 8.10             160.09 ± 6.83            159.29 ± 8.84            0.747
  Weight (kg) (mean ± standard deviation)      56.23 ± 9.597             59.25 ± 9.66             54.55 ± 9.32             0.137
  Male sex                                     20 (48)                   5 (33)                   15 (56)                  0.209
  Underlying disease                                                                                                       
      Charlson Comorbidity Index (mean ± SD)   4.71 ± 2.04               4.53 ± 1.51              4.81 ± 2.30              0.636
      Cardiovascular disease                   28 (67)                   12 (80)                  16 (59)                  0.306
      Chronic liver disease                    4 (10)                    2 (13)                   2 (7)                    0.608
      Diabetes mellitus                        21 (50)                   8 (53)                   13 (48)                  1.000
      Malignancy                               5 (12)                    0 (0)                    5 (19)                   0.142
      Neurological disease                     9 (21)                    2 (13)                   7 (26)                   0.451
      Peptic ulcer disease                     14 (33)                   5 (33)                   9 (33)                   1.000
      Connective tissue disease                1 (2)                     0 (0)                    1 (4)                    1.000
      Neutropenia                              0 (0)                     0 (0)                    0 (0)                    
  Septic shock                                 14 (33)                   5 (33)                   9 (33)                   1.000
  Polymicrobial bacteremia                     11 (26)                   3 (20)                   8 (30)                   0.717
      *Acinetobacter baumannii*                2 (5)                     1 (7)                    1 (4)                    
      *Burkholderia cepacia* complex           1 (2)                     1 (7)                    0 (0)                    
      *Enterococcus faecalis*                  2 (5)                     1 (7)                    1 (4)                    
      *Enterococcus faecium*                   1 (2)                     0 (0)                    1 (4)                    
      *Escherichia coli*                       3 (7)                     1 (7)                    2 (7)                    
      *Klebsiella pneumoniae*                  3 (7)                     0 (0)                    3 (11)                   
      *Pseudomonas aeruginosa*                 1 (2)                     0 (0)                    1 (4)                    
      *Serratia marcescens*                    1 (2)                     1 (7)                    0 (0)                    
      *Stenotrophomonas maltophilia*           1 (2)                     0 (0)                    1 (4)                    
  Immunosuppressants use                       6 (14)                    0 (0)                    6 (22)                   0.056
  MRSA bacteremia source                                                                                                   0.981
      Bone and joint                           0 (0)                     0 (0)                    0 (0)                    
      Catheter-related                         11 (26)                   4 (27)                   7 (26)                   
      Endocarditis                             2 (5)                     0 (0)                    2 (7)                    
      Pneumonia                                6 (14)                    2 (13)                   4 (15)                   
      Surgical wound or skin and soft tissue   6 (14)                    2 (13)                   4 (15)                   
      Unknown                                  17 (41)                   7 (47)                   10 (37)                  
  Vancomycin MIC (mg/L) (mean ± SD)                                                                                        0.075
      \< 0.5                                   7 (16)                    5 (33)                   2 (7)                    
      1                                        29 (69)                   9 (60)                   20 (74)                  
      1.5                                      2 (5)                     1 (7)                    1 (4)                    
      2                                        4 (10)                    0 (0)                    4 (15)                   
  Concurrent antibiotics                       31 (74)                   10 (67)                  21 (78)                  0.481
      Penicillin group                         6 (14)                    2 (13)                   4 (15)                   
      Cephalosporin group                      24 (57)                   6 (40)                   18 (67)                  
      Carbapenem group                         8 (19)                    1 (7)                    7 (26)                   
      Fluoroquinolone                          1 (2)                     0 (0)                    1 (4)                    
      Trimethoprim/sulfamethoxazole            3 (7)                     2 (13)                   1 (4)                    
      Aminoglycoside                           1 (2)                     0 (0)                    1 (4)                    
      Colistin                                 1 (2)                     0 (0)                    1 (4)                    
      Antifungal agents                        1 (2)                     0 (0)                    1 (4)                    
      Antiviral agents                         2 (5)                     0 (0)                    2 (7)                    

SD: standard deviation. MRSA: methicillin-resistant *Staphylococcus aureus*.

10.1371/journal.pone.0193585.t002

###### Vancomycin dosing profile, serum concentrations, and 30-day mortalities in total, success, and failure groups.

![](pone.0193585.t002){#pone.0193585.t002g}

                                             Total patients (N = 42)   Success group (N = 15)   Failure group (N = 27)   *p* value
  ------------------------------------------ ------------------------- ------------------------ ------------------------ --------------------------------------------
  Vancomycin dosage                                                                                                      
      Loading dose (mg/kg) (mean ± SD)       17.95±5.97                17.29±4.02               18.32±6.86               0.546
      Maintenance dose (mg/kg) (mean ± SD)   8.54±1.71                 8.55±2.15                8.54±1.45                0.992
  C~pre-HD~ (mean ± SD)                      16.00±4.43                17.40±4.55               15.22±4.24               0.139
      ≥ 15 mg/L                              26 (62)                   11 (73)                  15 (56)                  0.330
  C~pre-HD~/MIC ratio (mean ± SD)            17.75±8.88                22.80±10.90              14.94±6.11               0.019[\*](#t002fn002){ref-type="table-fn"}
      ≥ 18.6                                 16 (38)                   10 (67)                  6 (22)                   0.008[\*](#t002fn002){ref-type="table-fn"}
  30-days mortality                          7(17)                     2(13)                    5(19)                    1.000

SD: standard deviation. C~pre-HD~: pre-dialysis trough serum concentration. MIC: minimum inhibitory concentration.

\* p\<0.05

In the treatment failure group, the antibiotic agent was switched from vancomycin to daptomycin in 16 patients and linezolid in 1 patient based on physicians\' judgement and clinical situations. MRSA was eventually eradicated in 12 of the 16 patients, and 7 of them had negative blood culture within 7 days of daptomycin treatment. Only two patients failed to achieve blood culture conversion under daptomycin, and 2 patients did not have subsequent blood culture collected after daptomycin use.

The prediction power of C~pre-HD~/MIC for treatment outcome was evaluated using the ROC curve analysis. The optimal cut-off value of C~pre-HD~/MIC was 18.6, with the sensitivity of 67% and the specificity of 78%. The area under the ROC curve was 0.74 (95% confidence interval: 0.58--0.90, *p* = 0.011) ([Fig 1](#pone.0193585.g001){ref-type="fig"}), and the positive predictive value and negative predictive value were 62.5% and 81%, respectively.

![The receiver operating characteristic (ROC) curve of the C~pre-HD~/MIC at the cut-off value of 18.6 for the prediction of treatment outcomes.\
CI: confidence interval.](pone.0193585.g001){#pone.0193585.g001}

Discussion {#sec009}
==========

This is the first study known to the authors focusing on the correlation between the C~pre-HD~ of vancomycin and the treatment outcomes for MRSA bacteremia in dialysis patients. The relationship between vancomycin C~trough~, AUC~24~/MIC, and the clinical outcomes for MRSA infection has been well studied in the general population, and that C~trough~ of 15 mg/L or higher, corresponded to the AUC~24~/MIC \> 400, was recommended by the IDSA guideline\[[@pone.0193585.ref002]--[@pone.0193585.ref007], [@pone.0193585.ref017], [@pone.0193585.ref018]\]. This standard was extrapolated for patients who received renal replacement therapy in clinical practice without adequate studies to explore the correlation between this target concentration and treatment outcome in this particular patient population. Until now, all relevant studies were designed to test if the dosing strategies would achieve the target C~pre-HD~ of 15--20 mg/L in patients who were on intermittent HD\[[@pone.0193585.ref012], [@pone.0193585.ref014]\]. However, it has not been demonstrated whether the specific target C~pre-HD~ can be translated into good clinical outcomes.

According to the results of our study, the success and failure groups did not have significant differences in the mean C~pre-HD~ as well as the proportion of patients with the C~pre-HD~ \> 15 mg/L. However, after taking MIC into consideration, C~pre-HD~/MIC was significantly higher in the success group than that in failure group. Moreover, the ROC curve analysis suggested C~pre-HD~/MIC≧18.6 as an outcome predictor for treating MRSA bacteremia. Our data were also compatible with previous recommendations that the target level of vancomycin C~pre-HD~ should be 15--20 mg/L for a MIC of 1 mg/L\[[@pone.0193585.ref009]\]. As for the MIC distribution, around 70% of MRSA had vancomycin MIC value of 1 mg/L and pathogens with high MIC value (\>1.5 mg/L) were almost distributed in treatment failure group, which was compatible with previous studies that high MIC level was a predict factor for poor treatment outcome.\[[@pone.0193585.ref019]\] However, it is difficult to distinguish to what degree is the failure caused by not attaining the PK/PD target and to what degree the higher MIC caused failure. Therefore, we excluded patients who suffered from pathogens with high MIC value (\>1.5 mg/L), and the C~pre-HD~/MIC was still significantly higher in treatment success group than that in failure group (24.07 vs. 16.92, p = 0.04). This result demonstrated that attaining the optimal C~pre-HD~/MIC was important for treatment outcome of MRSA bacteremia in this population. Because vancomycin MIC crept in MRSA, which had high percentage of vancomycin MIC of 1 mg/L, and nephrotoxicity is generally not an issue in patients receiving HD, the aggressive vancomycin dosing strategy to achieve C~pre-HD~≧18.6 mg/L should be adopted before confirming MIC data\[[@pone.0193585.ref020]\].

Compared with a similarly designed study of vancomycin treatment in non-dialysis patients with MRSA bacteremia, the treatment success rate in this study was much lower (36% vs. 67.5%) despite of similar Charlson Comorbidity Index\[[@pone.0193585.ref004]\]. Two factors may explain the difference. First, the immune function is depressed in patients with renal failure. Functional abnormalities of monocytes, lymphocytes, neutrophils, and dendritic cells are directly linked with infection risk and treatment failure in this patient population.\[[@pone.0193585.ref008]\] Second, the formation of bacterial biofilm in dialysis patients may contribute to the high treatment failure rate. *Staphylococcus aureus* is the most common gram-positive organism involving in biofilm infection in dialysis patients \[[@pone.0193585.ref021], [@pone.0193585.ref022]\]. Some studies revealed that dialysis-related biofilm infections are difficult to eradicate as they developed antibiotic resistance\[[@pone.0193585.ref023]--[@pone.0193585.ref025]\]. Vancomycin has poor penetration into biofilm compared with daptomycin, and it is reasonable that the patients responded to daptomycin treatment in this study after vancomycin treatment failure.\[[@pone.0193585.ref026]\] Further studies are necessary to determine if daptomycin has better treatment effect than vancomycin in dialysis patients.

A multivariate analysis was performed by logistic regression. The covariates such as C~pre-HD~/MIC, Charlson Comorbidity Index, polymicrobial bacteremia, concurrent antibiotic use and septic shock were put into regression model, and found that C~pre-HD~/MIC was still the only significant variables to affect treatment outcome (OR:1.14, *p* = 0.013). Although more patients received immunosuppressants in treatment failure group than that in success group and this may confound our result, it did not put into regression model due to the extremely unbalanced distribution that patients received immunosuppressants all belonged to treatment failure group. Therefore, we tried to exclude these subjects and found that C~pre-HD~/MIC was still significantly different between the two groups (*p* = 0.035). This may further increase the strength of our conclusion that C~pre-HD~/MIC was a predictor for treatment outcome of MRSA bacteremia in renal failure patients receiving HD.

Based on our vancomycin dosing protocol for patients receiving HD three times per week, the proportion of C~pre-HD~ ≧ 18.6 mg/L was only 21%, which may have contributed to the relatively high rate of treatment failure. One possible cause for this low proportion of therapeutic C~pre-HD~ was that the loading dose used in the present study (\<20 mg/kg) was too low. Vandecasteele et al. showed that a fixed loading dose of 20 mg/kg led to C~pre-HD~ ≥ 15 mg/L in only one-half of patients\[[@pone.0193585.ref009]\], supporting that a higher loading dose should be applied in order to achieve the optimal therapeutic C~pre-HD~.

There are several limitations of our study. First, the sample size was quite small in this study because of the low MRSA prevalence rate and MIC report has been available since 2013 in our institution. Further large prospective study is needed to confirm the treatment target provided by this study. Second, we only enrolled patients undergoing HD; this result may not apply to patients receiving other renal replacement therapy, such as peritoneal dialysis. Third, this was a retrospective study, and thus was not controlled for some confounding factors. Finally, overweight and obese patients were not represented in this study. Therefore, the result may not apply to this special population.

Conclusions {#sec010}
===========

We showed that C~pre-HD~/MIC was associated with the outcome of vancomycin treatment in dialysis patients with MRSA bacteremia. Targeting to achieve a C~pre-HD~/MIC of ≧ 18.6 may improve the treatment outcomes in renal failure patients who are on intermittent HD.
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